Prasinezumab |
| カタログ番号GC72383 |
Prasinezumab (PRX 002)は人間に影響されIgG1モノクローナル抗体セクターに対する集約α-synuclein。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1960462-19-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Prasinezumab against an epitope in the carboxyl terminus of human α-synuclein. Prasinezumab binds to human aggregated α-synuclein with a high affinity and avidity[1].
References:
[1]. Gennaro Pagano, et al. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. Front Neurol. 2021 Oct 1;12:705407.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *